|
|
 |
 |
 |
Differential Uptake of PEG-Silica-FITC Nanoparticles by Human Breast Cancer Cells and Normal Human Breast Epithelial Cells
N. Iwakuma, P. Sharma, M.J. Delano, L.L. Moldawer, B.M. Moudgil and S.R. Grobmyer University of Florida, US
Keywords: silica nanoparticles, breast cancer, normal breast epithelial cells, cellular uptake, flow cytometry
Abstract: Background: An understanding of uptake of nanoparticles (NPs) by human cancer cells and non-cancer cells is important for the development of NPs as novel cancer therapeutic and diagnostic agents. Hypothesis: Uptake of NPs is increased in human breast cancer cells compared to normal human breast epithelial cells. Methods: PEGylated-FITC silica NPs (150nm, [1.18mg/mL]) were synthesized. Human breast cancer cell lines (MCF-7, BT474) and normal human breast epithelial cells were (MCF10A) cultured. Cells were exposed to NPs for 24h. A quantitative analysis (Flow-Cytometry) and qualitative analysis of cellular uptake (Fluorescence microscopy) were performed. Results: Exposure of cells to NPs did not affect cell viability. After incubation of cells with 20 l of NPs, increased uptake of PEG-silica-FITC NPs was seen in cancer cells (MCF-7, 18.5%; BT474, 16.8%) compared to non-cancer cells (MCF-10A, 9.9%). Incubation of cells with 40 l of NPs demonstrated that uptake of NPs is dose related and confirmed preferential uptake of NPs by cancer cells (MCF-7, 27.3%; BT474, 25.2%) compared to non-cancer cells (MCF-10A, 12.3%). Conclusion: Human breast cancer cells demonstrate increased uptake of NPs compared to normal human breast epithelial cells. This observation has important implications for the development of NPs as cancer therapeutic and/or diagnostic agents.
Back to Program
Nanotech 2007 Conference Program Abstract
|